GLP-1 NAION Lawsuit MDL 3163 Case Management Orders (CMOs)
Below is the chronological log of Case Management Orders (CMOs) and foundational legal filings entered in MDL 3163: In Re: GLP-1 Receptor Agonists NAION Products Liability Litigation.
This litigation handles lawsuits alleging that certain GLP-1 receptor agonists (such as Ozempic) can cause Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). NAION is a severe eye complication that can lead to permanent vision loss.
Like its sister litigation (MDL 3094, which handles gastrointestinal injuries caused by GLP-1s), MDL 3163 is centralized in the U.S. District Court for the Eastern District of Pennsylvania under the supervision of the Honorable Karen Spencer Marston.
Bookmark this page to stay updated on the latest scheduling, protocols, and legal updates regarding the GLP-1 vision loss lawsuits.
Chronological Index of MDL 3163 Orders
- 05/04/2026: Case Management Order No. 11 (Exhibit 2) – Sealing Process Order [PDF]
- 05/04/2026: Case Management Order No. 11 (Exhibit 1) – Qualified Protective Order [PDF]
- 05/04/2026: Case Management Order No. 11 – Qualified Protective Order & Sealing Process Order [PDF]
- 04/30/2026: Case Management Order No. 10 – Order Governing Defendants’ Production of Electronically Stored Information (ESI) [PDF]
- 04/30/2026: Case Management Order No. 9 – Privilege Logging Order [PDF]
- 03/16/2026: Case Management Order No. 8 – Rule 502(d) Non-Waiver Order [PDF]
- 03/16/2026: Case Management Order No. 7 – Evidence Preservation Order [PDF]
- 03/16/2026: Case Management Order No. 6 – Science Day Scheduling Order [PDF]
- 02/23/2026: Case Management Order No. 5 – Appointment of Plaintiffs’ Counsel Leadership [PDF]
- 01/29/2026: Case Management Order No. 4 – Direct Filing Order [PDF]
- 01/15/2026: Case Management Order No. 3 – Establishment of Streamlined Docket [PDF]
- 12/23/2025: Case Management Order No. 2 – Application to Appear Pro Hac Vice [PDF]
- 12/23/2025: Case Management Order No. 1 – Notice of Initial Case Management Conference and Preliminary Stay [PDF]
Key Context & Litigation Overview
What is NAION?
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurs when blood flow to the optic nerve head is compromised, causing sudden, irreversible vision loss, typically impacting only one eye at a time. Recent clinical data and case reports have discovered a potential vascular or metabolic link between rapid glycemic changes caused by semaglutide/GLP-1 receptor agonists and the onset of ischemic optic events.
Why is there a Separate GLP-1 Docket for NAION (MDL 3163)?
While the initial GLP-1 MDL (MDL 3094) focuses extensively on systemic gastrointestinal injuries, such as gastroparesis, bowel obstructions, and ileus, the distinct medical, scientific, and causation arguments surrounding blindness and optic nerve damage required a targeted management framework. Judge Marston utilizes a streamlined structure to handle these unique injury claims efficiently and separately from the GI injuries. Having both GLP-1 MDLs under the same judge creates numerous efficiencies, because the judge already has a baseline understanding of GLP-1s and the defendants.
Free GLP-1 Case Evaluation & Consultations
If you or a loved one used a GLP-1 receptor agonist (such as Ozempic, Wegovy, or Rybelsus) and subsequently suffered severe vision loss or were diagnosed with NAION, you may be entitled to financial compensation.
Our legal team has decades of combined experience fighting pharmaceutical companies to recover damages for defective medications and failure-to-warn claims.
- Phone: (202) 792-7927
- Email: intake@nighgoldenberg.com
- Hours: Mon–Fri, 8:00 a.m. – 5:00 p.m.
Disclaimer: This page is for informational purposes only and does not constitute formal legal advice. Uploaded PDFs and docket updates are pulled directly from the Eastern District of Pennsylvania (EDPA) public access records.
